Heron Announces Positive Topline Results from Phase 2b Clinical Studies of HTX-011 in Total Knee Arthroplasty and Breast Augmentation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Heron Announces Positive Topline Results from Phase 2b Clinical Studies of HTX-011 in Total Knee Arthroplasty and Breast Augmentation
June 21, 2018 10:47 AM EDT
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $40 price target on Heron Therapeutics (NASDAQ: HRTX) announced positive top-line results from two additional studies which will support the NDA filing for HTX-011 and expand the commercial opportunity for the drug.
"This... More
June 21, 2018 8:05 AM EDT
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that HTX-011 for postoperative pain management has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA). HTX-011 is an investigational, long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for the management of postoperative pain.
Breakthrough Therapy designation is designed to expedite the development... More
